N/A N=15 Effect on Acetaminophen Metabolism by Liquid Formulations
Acetaminophen Metabolism · Acetaminophen Poisoning · Drug Metabolism by Excipients
Primary: Acetaminophen Metabolites — 2.411; 2.009 mcg.hr/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=95 Effect of Race/Ethnicity and Genes on Acetaminophen Pharmacokinetics
Pain · Fever · Hepatotoxicity
Primary: Acetaminophen Plasma Clearance Association With Race/Ethnicity — 5.3; 5.9 mL/min/kg — p=0.52
Phase 4 N=27 Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days
Drug Induced Liver Injury
Primary: Serum Level of Acetaminophen-cysteine (APAP-Cys) Protein Adducts — 0.0; 0.3; 0.3; 0.4 nmol/mL
Phase 4 N=21 Protective Effects of Propylene Glycol in Daily Acetaminophen Dosing
Acetaminophen Toxicity
Primary: Rise in Plasma Transaminases: Proportion of Responders. — 6; 8 Participants — p=0.59
N/A N=30 Pharmacokinetics of Acetaminophen in Pediatric Patients With Congenital Heart Disease
Congenital Heart Disease
Primary: Acetaminophen Serum Concentrations — 19; 17; 13; 13 mcg/mL
Phase 4 N=276 Aminotransferase Trends During Prolonged Acetaminophen Dosing
Drug Toxicity · Healthy
Primary: The Proportion of Subjects Treated With Long-term Acetaminophen (4 g/Day) That Develops Persistent ALT Elevations. — 204; 47; 1; 0 participants
N/A N=55 Mechanisms of Action of Acetaminophen
Myocardial Infarction · Arthritis
Primary: Percent Change in Serum Thromboxane B2 — 97.0; 97.4; 98.3; 96.7 Percent inhibition of baseline — p=>0.05
N/A N=11 Tylenol Levels in Bariatric Patients
Obesity
Primary: Intra- and Post-operative Serum Concentrations — 17; 14; 9; 5 µg.mL-1
Phase 1 N=75 Safety and Pharmacokinetic (PK) Study of Intravenous (IV) Acetaminophen Administration in Pediatric Inpatients
Pain · Fever
Primary: Single-dose Maximum Plasma Concentration (Cmax) , Micrograms Per Milliliter (µg/mL) Pharmacokinetics of IV Acetaminophen — 40.1; 20.1; 16.7; 19.3 micrograms per…
Phase 2 N=44 Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis
Severe Sepsis
Primary: F2-isoprostanes After 72 Hours of Acetaminophen or Placebo — 33.4; 40.15 pg/mL — p=0.353
Phase 2 N=250 Analgesic Effect of IV Acetaminophen in Tonsillectomies
Adenotonsillitis · Tonsillitis
Primary: FLACC Pain Score Greater Than or Equal to 4 — 58; 69 Participants
N/A N=60 Inhibition of Lipid Peroxidation During Cardiac Surgery
Cardiopulmonary Bypass Induced Lipid Peroxidation
Primary: Plasma Isofuran Concentrations — 61.5; 67.7; 72.1; 82.7 pg/mL — p=0.05
Phase 3 N=60 Safety of Intravenous Acetaminophen Vs Placebo for the Treatment of Endotoxin-Induced Fever in Healthy Adult Males
Fever
Primary: Weighted Sum of Temperature Differences Over 6 Hours (WSTD6) Assessment of the Antipyretic Effect Over 6 h of a Single Dose of IV APAP vs. Placebo for Treatment of…
Phase 4 N=393 Acetaminophen (APAP) +/- Oxycodone
Musculoskeletal Pain
Primary: Change in Pain Assessment — 2.9; 4.0 score on a scale
Phase 3 N=100 Study of the Safety & Efficacy of Intravenous Acetaminophen in Pediatric Inpatients
Pain · Fever
Primary: Number of Subjects Reporting at Least One Treatment Emergent Adverse Event (TEAE) — 1; 1; 5; 25 Subjects
Phase 3 N=213 Safety and Efficacy of Intravenous Acetaminophen (IV APAP) in Adult Inpatients
Acute Pain · Fever
Primary: Number of Subjects Reporting at Least One Treatment-Emergent Adverse Event (TEAE). — 77; 86; 26 Participants
Phase 4 N=50 Drug Interactions Between Morphine and Orally or IV Administered Acetaminophen
Pain
Primary: Area Under the Plasma Concentration-time Curve Over 6 Hours (AUC6) for Acetaminophen — 31.00; 28.51; 25.31; 52.38 hour*microgram per milliliter (h*mcg/mL)
Phase 4 N=120 Preoperative IV Versus Oral Acetaminophen
Pain, Postoperative
Primary: Patient Reported Pain — 4.12; 4.37 score on a scale
N/A N=34 Acetaminophen and Impaired Musculoskeletal Adaptations to Exercise Training
Sarcopenia · Osteoporosis · Aging
Primary: Change in Total Body Fat-free Mass — 1.5; 2.3; 0.7 kg — p=0.38
N/A N=274 Pathogenesis of Adverse Drug Reactions
Seizures
Primary: Drug (Valproic Acid or Carbamazepine) Metabolite Profiles in Urine — 15.2; 13.1; 1.15; 2.13 nmol per mg creatinine
Phase 4 N=41 Effects of Intravenous Acetaminophen on Body Temperature and Hemodynamic Responses in Febrile Critically Ill Adults
Fever · Critical Illness
Primary: Core Body Temperature — 38.4; 37.9 degrees Celsius — p=0.002
Phase 3 N=105 Study of the Efficacy and Safety of Intravenous vs Oral Acetaminophen for Treatment of Fever in Healthy Adult Males
Fever
Primary: The Rapidity of Onset of Antipyretic Effect at 2 Hours (Measured as Weighted Sum of Temperature Differences Over 2 Hours, WSTD2) — 0.3; 0.6 Degrees Celsius
Phase 4 N=100 Intravenous Acetaminophen in Craniotomy
Postoperative Pain
Primary: Post-Operative Opioid Requirement — 11.0; 10.1 Morphine Equivalents
Phase 1 N=24 PP100-01 (Calmangafodipir) for Overdose of Paracetamol
Paracetamol Overdose
Primary: Safety Events — 6; 6; 6; 6 participants
Phase 4 N=41 Acetaminophen's Efficacy For Post-operative Pain
Tonsillitis · Airway Obstruction · Difficulty Swallowing
Primary: Total Pain Medication — 1.7; 2.2 mg
Phase 4 N=74 Modified Pre-operative Oral Doses Acetaminophen Versus Intravenous Acetaminophen
Tonsillectomy · Adenoidectomy
Primary: Total Dose of Opioid — 147.6; 125.4 mcg/kg — p=0.127
N/A N=14 Pharmacotoxicology of Trichloroethylene Metabolites
Congenital Lactic Acidosis
Primary: Hypothesize That Subject's Genotype Will Determine How DCA is Metabolized. — 1592; 232 Minutes — p=0.023
Phase 3 N=580 Effect of Intravenous Acetaminophen on Postoperative Opioid-related Complications
Postoperative Pain
Primary: Duration of Hypoxemia — 0.7; 1.1 min/h — p=0.29
Phase 4 N=68 Efficacy of IV Acetaminophen for Pain Management
Post-operative Pain
Primary: Opioid Rescue - 48 Hours — 54.4803; 48.9253 Milligrams of intravenous morphine equiv — p=.356
Phase 2 N=488 Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery
Acute Respiratory Distress Syndrome · Critical Illness · Respiratory Failure
Primary: Days Alive and Free of Organ Support to Day 28 — 20.2; 20.5; 19.7; 18.4 days — p=0.65